Iopofosine I 131 - Cellectar Biosciences
Alternative Names: (131)I-CLR1404; 131-I-NM404; 131I-CLR1404; CLR 1404 I-131; CLR-131; HOT; I-131-CLR1404; NM-404Latest Information Update: 04 Jun 2024
At a glance
- Originator University of Michigan Medical School
- Developer Cellectar Biosciences; University of Wisconsin-Madison
- Class Antineoplastics; Drug conjugates; Iodine radioisotopes; Phospholipid ethers; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Haematological malignancies; Multiple myeloma; Waldenstrom's macroglobulinaemia
- Phase I/II Non-small cell lung cancer
- Phase I Brain cancer; Glioma; Head and neck cancer; Lymphoma; Solid tumours
Most Recent Events
- 29 May 2024 Cellectar Biosciences entered into a collaboration with City of Hope Cancer Center to evaluate Iopofosine I 131 in Mycosis Fungoides
- 29 May 2024 Cellectar Biosciences and City of Hope Cancer Center plans to initiate a clinical trial for Mycosis Fungoides in late 2024 or early 2025.
- 27 Mar 2024 Cellectar Biosciences announces intention to submit NDA for Waldenstrom’s macroglobulinemia in March 2024